Strides Pharma Science Ltd
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
- Market Cap ₹ 12,504 Cr.
- Current Price ₹ 1,360
- High / Low ₹ 1,395 / 452
- Stock P/E 190
- Book Value ₹ 388
- Dividend Yield 0.18 %
- ROCE 4.83 %
- ROE 2.02 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 108%
Cons
- Stock is trading at 3.51 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 6.97% over past five years.
- Tax rate seems low
- Company has a low return on equity of 2.61% over last 3 years.
- Promoters have pledged 64.6% of their holding.
- Company has high debtors of 256 days.
- Promoter holding has decreased over last 3 years: -3.76%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
712 | 1,064 | 929 | 2,162 | 1,382 | 1,470 | 1,537 | 1,692 | 1,858 | 1,979 | 1,854 | 2,153 | 2,233 | |
616 | 914 | 795 | 1,894 | 1,255 | 1,271 | 1,402 | 1,487 | 1,698 | 1,902 | 1,755 | 1,898 | 1,972 | |
Operating Profit | 96 | 150 | 134 | 268 | 127 | 199 | 135 | 205 | 159 | 77 | 100 | 256 | 261 |
OPM % | 13% | 14% | 14% | 12% | 9% | 14% | 9% | 12% | 9% | 4% | 5% | 12% | 12% |
54 | 4,614 | 619 | 82 | 154 | 860 | 111 | 93 | 117 | 123 | 68 | 67 | 67 | |
Interest | 71 | 105 | 34 | 103 | 72 | 82 | 54 | 67 | 65 | 74 | 139 | 168 | 178 |
Depreciation | 19 | 47 | 49 | 103 | 70 | 78 | 83 | 94 | 99 | 104 | 94 | 85 | 84 |
Profit before tax | 60 | 4,612 | 669 | 145 | 139 | 899 | 109 | 136 | 112 | 22 | -65 | 70 | 66 |
Tax % | 7% | 24% | 20% | 10% | 22% | 1% | -1% | 12% | 30% | -738% | -107% | 6% | |
56 | 3,513 | 532 | 130 | 109 | 892 | 110 | 120 | 78 | 180 | 5 | 65 | 61 | |
EPS in Rs | 9.52 | 589.42 | 89.32 | 14.58 | 12.14 | 99.62 | 12.33 | 13.43 | 8.72 | 20.07 | 0.52 | 7.13 | 6.69 |
Dividend Payout % | 21% | 86% | 121% | 34% | 37% | 2% | 24% | 104% | 29% | 0% | 289% | 35% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 7% |
3 Years: | 5% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | -4% |
5 Years: | -8% |
3 Years: | -2% |
TTM: | -25% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 28% |
3 Years: | 32% |
1 Year: | 183% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 3% |
3 Years: | 3% |
Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 59 | 60 | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 |
Reserves | 1,313 | 1,571 | 1,415 | 3,068 | 3,143 | 3,073 | 3,167 | 3,069 | 3,158 | 3,317 | 3,348 | 3,469 |
634 | 473 | 405 | 1,545 | 1,608 | 606 | 811 | 902 | 917 | 1,284 | 1,414 | 1,650 | |
293 | 337 | 273 | 602 | 641 | 517 | 595 | 616 | 1,056 | 743 | 768 | 627 | |
Total Liabilities | 2,299 | 2,440 | 2,152 | 5,304 | 5,481 | 4,285 | 4,663 | 4,677 | 5,221 | 5,434 | 5,620 | 5,838 |
306 | 381 | 394 | 984 | 1,194 | 564 | 574 | 651 | 644 | 617 | 597 | 556 | |
CWIP | 30 | 37 | 39 | 180 | 158 | 144 | 122 | 112 | 111 | 56 | 55 | 94 |
Investments | 1,295 | 1,047 | 968 | 2,447 | 2,520 | 1,777 | 2,149 | 2,171 | 2,395 | 2,400 | 2,492 | 2,498 |
668 | 976 | 750 | 1,693 | 1,609 | 1,801 | 1,818 | 1,743 | 2,072 | 2,361 | 2,476 | 2,689 | |
Total Assets | 2,299 | 2,440 | 2,152 | 5,304 | 5,481 | 4,285 | 4,663 | 4,677 | 5,221 | 5,434 | 5,620 | 5,838 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | -3 | 207 | 83 | 412 | 66 | 40 | 138 | 283 | -283 | 242 | -36 | |
901 | 3,999 | 305 | -1,062 | -883 | 433 | -166 | 63 | -276 | 19 | -183 | -61 | |
-962 | -3,498 | -802 | 1,571 | -67 | -707 | 123 | -204 | -49 | 251 | 11 | 108 | |
Net Cash Flow | -50 | 497 | -290 | 592 | -538 | -208 | -3 | -3 | -42 | -13 | 70 | 11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 99 | 94 | 101 | 117 | 143 | 112 | 138 | 141 | 161 | 239 | 257 | 256 |
Inventory Days | 98 | 80 | 110 | 113 | 204 | 126 | 197 | 189 | 254 | 170 | 168 | 155 |
Days Payable | 134 | 127 | 133 | 148 | 234 | 183 | 212 | 200 | 271 | 213 | 220 | 166 |
Cash Conversion Cycle | 63 | 47 | 77 | 82 | 112 | 55 | 123 | 130 | 144 | 196 | 205 | 244 |
Working Capital Days | 131 | 100 | 97 | 120 | 110 | 150 | 178 | 150 | 162 | 231 | 261 | 292 |
ROCE % | 9% | 11% | 9% | 6% | 5% | 24% | 4% | 5% | 4% | 2% | 2% | 5% |
Documents
Announcements
- Announcement Under Regulation 30 On Partial Redemption Of Non Convertible Debentures 1d
- Business Responsibility and Sustainability Reporting (BRSR) 1d
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300mg and 450mg
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Sep - Newspaper publication for 33rd AGM notice of FY24
- Reg. 34 (1) Annual Report. 2 Sep
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
About[1]
Incorporated in 1990, Strides operates in the pharmaceutical industry, manufacturing generic formulations in various dosage forms.